Abstract Glucagon-like peptide-1 (GLP-1) is a member of the proglucagon incretin family
implicated in the control of appetite and satiety. GLP-1 has insulinotropic, insulinomimetic …

Cardiovascular disease is a leading cause of death in the United States and across the
world, and better therapies are constantly being sought to improve patient outcomes. Recent …

Abstract Glucagon-like peptide 1 (GLP-1) is an incretin hormone responsible for
amplification of insulin secretion when nutrients are given orally, as opposed to …

Recently, the crucial role of GLP-1 in cardiovascular disease has been suggested by both
preclinical and clinical studies. In vivo and in vitro studies have demonstrated cardio …

Glucagon-like peptide 1 (GLP1) is a major incretin hormone. This means that it is secreted
by the gut in response to food and helps in reducing post-prandial glucose exertion. It …

Type 2 diabetes mellitus (T2DM) is a highly prevalent disease that is associated with
development of atherosclerosis and an increase in all-cause mortality. Treatment options for …

Glucagon‐like peptide‐1 (GLP‐1) is an incretin hormone secreted by the small intestine in
response to nutrient ingestion. It has wide‐ranging effects on glucose metabolism, including …

Although the insulinotropic role of glucagon-like peptide-1 (GLP-1) in type 2 diabetes
mellitus has been substantiated, its role in cardioprotection remains largely unknown. To …

Abstract Glucagon-like peptide-1 (GLP-1) is an incretin hormone that has been shown to
have hemodynamic and cardioprotective capacity in addition to its better characterized …

Summary Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone
responsible for the release of insulin in response to food. Pre-clinical and human …